Gossamer Bio: UBS Raises Rating and Price Target - Probability of Success for Seralutinib Underestimated, According to Analyst

Gossamer Bio Inc. (GOSS) positions itself as a company focused on the development and commercialization of innovative therapies for pulmonary hypertension (PH). The main product in its development pipeline is Seralutinib, an inhalable tyrosine kinase inhibitor (TKI). Seralutinib aims to address the underlying pathophysiology of PH by inhibiting signaling pathways such as PDGFRα/β, CSF1R, and c-KIT. Unlike the often merely symptomatic vasodilators, Seralutinib seeks to reverse vascular remodeling and thus combat the actual cause of the disease....